Literature DB >> 19264857

Intra- and intersubject whole blood/plasma cannabinoid ratios determined by 2-dimensional, electron impact GC-MS with cryofocusing.

Eugene W Schwilke1, Erin L Karschner, Ross H Lowe, Ann M Gordon, Jean Lud Cadet, Ronald I Herning, Marilyn A Huestis.   

Abstract

BACKGROUND: Whole-blood concentrations of Delta(9)-tetrahydrocannabinol (THC), 11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (THCCOOH) are approximately half of those in plasma due to high plasma protein binding and poor cannabinoid distribution into erythrocytes. Whole blood is frequently the only specimen available in forensic investigations; controlled cannabinoid administration studies provide scientific data for interpretation of cannabinoid tests but usually report plasma concentrations. Whole-blood/plasma cannabinoid ratios from simultaneously collected authentic specimens are rarely reported.
METHODS: We collected whole blood for 7 days from 32 individuals residing on a closed research unit. Part of the whole blood was processed to obtain plasma, and the whole blood and plasma were stored at -20 degrees C until analysis by validated 2-dimensional GC-MS methods.
RESULTS: We measured whole-blood/plasma cannabinoid ratios in 187 specimen pairs. Median (interquartile range) whole-blood/plasma ratios were 0.39 (0.28-0.48) for THC (n = 75), 0.56 (0.43-0.73) for 11-OH-THC (n = 17), and 0.37 (0.24-0.56) for THCCOOH (n = 187). Intrasubject variability was determined for the first time: 18.1%-56.6% CV (THC) and 10.8%-38.2% CV (THCCOOH). The mean whole-blood/plasma THC ratio was significantly lower than the THCCOOH ratio (P = 0.0001; 4 participants' mean THCCOOH ratios were >0.8).
CONCLUSIONS: Intra- and intersubject whole-blood/plasma THC and THCCOOH ratios will aid interpretation of whole-blood cannabinoid data.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19264857      PMCID: PMC3197018          DOI: 10.1373/clinchem.2008.114405

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  23 in total

1.  In vivo binding of delta 1-tetrahydrocannabinol and cannabinol to rat serum proteins.

Authors:  N K McCallum; M E Eastwood
Journal:  J Pharm Pharmacol       Date:  1978-06       Impact factor: 3.765

2.  Binding of delta-1-tetrahydrocannabinol to human plasma proteins.

Authors:  M Wahlqvist; I M Nilsson; F Sandberg; S Agurell
Journal:  Biochem Pharmacol       Date:  1970-09       Impact factor: 5.858

3.  Delta(9)-THC, 11-OH-Delta(9)-THC and Delta(9)-THCCOOH plasma or serum to whole blood concentrations distribution ratios in blood samples taken from living and dead people.

Authors:  C Giroud; A Ménétrey; M Augsburger; T Buclin; P Sanchez-Mazas; P Mangin
Journal:  Forensic Sci Int       Date:  2001-12-01       Impact factor: 2.395

4.  Stability of delta-9-tetrahydrocannabinol in stored blood and serum.

Authors:  A S Wong; M W Orbanosky; V C Reeve; J D Beede
Journal:  NIDA Res Monogr       Date:  1982

5.  How to improve estimates of imprecision.

Authors:  J S Krouwer; R Rabinowitz
Journal:  Clin Chem       Date:  1984-02       Impact factor: 8.327

6.  Binding of (+)- and (minus)-delta-1-tetrahydrocannabinols and (minus)-7-hydroxy-delta-1-tetrahydrocannabinol to blood cells and plasma proteins in man.

Authors:  M Widman; S Agurell; M Ehrnebo; G Jones
Journal:  J Pharm Pharmacol       Date:  1974-11       Impact factor: 3.765

7.  Partition coefficient, blood to plasma ratio, protein binding and short-term stability of 11-nor-Delta(9)-carboxy tetrahydrocannabinol glucuronide.

Authors:  Gisela Skopp; Lucia Pötsch; Martin Mauden; Barbara Richter
Journal:  Forensic Sci Int       Date:  2002-03-28       Impact factor: 2.395

8.  125I radioimmunoassay of delta-9-tetrahydrocannabinol in blood and plasma with a solid-phase second-antibody separation method.

Authors:  S M Owens; A J McBay; H M Reisner; M Perez-Reyes
Journal:  Clin Chem       Date:  1981-04       Impact factor: 8.327

9.  Stability of delta 9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC in blood and plasma.

Authors:  J R Johnson; T A Jennison; M A Peat; R L Foltz
Journal:  J Anal Toxicol       Date:  1984 Sep-Oct       Impact factor: 3.367

10.  Confirmation of cannabinoids in meconium using two-dimensional gas chromatography with mass spectrometry detection.

Authors:  Stephanie J Marin; Rebecka Coles; Francis M Urry; Gwendolyn A McMillin
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-08-26       Impact factor: 3.205

View more
  16 in total

1.  Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration.

Authors:  David M Schwope; Erin L Karschner; David A Gorelick; Marilyn A Huestis
Journal:  Clin Chem       Date:  2011-08-11       Impact factor: 8.327

2.  Direct quantification of cannabinoids and cannabinoid glucuronides in whole blood by liquid chromatography-tandem mass spectrometry.

Authors:  David M Schwope; Karl B Scheidweiler; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2011-07-05       Impact factor: 4.142

3.  Postmortem redistribution of Δ9-tetrahydrocannabinol (THC), 11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (THCCOOH).

Authors:  Michael G Holland; David M Schwope; Robert Stoppacher; Shane B Gillen; Marilyn A Huestis
Journal:  Forensic Sci Int       Date:  2011-07-20       Impact factor: 2.395

4.  Plasma Cannabinoid Pharmacokinetics After Controlled Smoking and Ad libitum Cannabis Smoking in Chronic Frequent Users.

Authors:  Dayong Lee; Mateus M Bergamaschi; Garry Milman; Allan J Barnes; Regina H C Queiroz; Ryan Vandrey; Marilyn A Huestis
Journal:  J Anal Toxicol       Date:  2015-10       Impact factor: 3.367

Review 5.  A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics.

Authors:  Emily J Cox; Neha Maharao; Gabriela Patilea-Vrana; Jashvant D Unadkat; Allan E Rettie; Jeannine S McCune; Mary F Paine
Journal:  Pharmacol Ther       Date:  2019-05-07       Impact factor: 12.310

6.  Predictive model accuracy in estimating last Δ9-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC.

Authors:  Erin L Karschner; David M Schwope; Eugene W Schwilke; Robert S Goodwin; Deanna L Kelly; David A Gorelick; Marilyn A Huestis
Journal:  Drug Alcohol Depend       Date:  2012-03-29       Impact factor: 4.492

7.  Oral fluid and plasma cannabinoid ratios after around-the-clock controlled oral Δ(9)-tetrahydrocannabinol administration.

Authors:  Garry Milman; David M Schwope; Eugene W Schwilke; William D Darwin; Deanna L Kelly; Robert S Goodwin; David A Gorelick; Marilyn A Huestis
Journal:  Clin Chem       Date:  2011-08-29       Impact factor: 8.327

8.  Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450.

Authors:  Sumit Bansal; Neha Maharao; Mary F Paine; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2020-06-25       Impact factor: 3.922

9.  Extended plasma cannabinoid excretion in chronic frequent cannabis smokers during sustained abstinence and correlation with psychomotor performance.

Authors:  Erin L Karschner; Madeleine J Swortwood; Jussi Hirvonen; Robert S Goodwin; Wendy M Bosker; Johannes G Ramaekers; Marilyn A Huestis
Journal:  Drug Test Anal       Date:  2015-06-11       Impact factor: 3.345

10.  Implications of plasma Delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers.

Authors:  Erin L Karschner; Eugene W Schwilke; Ross H Lowe; W David Darwin; Ronald I Herning; Jean Lud Cadet; Marilyn A Huestis
Journal:  J Anal Toxicol       Date:  2009-10       Impact factor: 3.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.